Faes Farma considers alliances and acquisitions in Spain and abroad
Faes Farma estudia alianzas y compras en España y en el exterior
Intel ID : 224160
Synopsis |
Spanish pharmaceutical group Faes Farma is considering acquisitions in Spain and abroad, to strengthen its business. The company expects to close 2015 with profits of EUR 29m, a 16% increase compared with 2014, and reaching revenues of EUR 205m. The part destined for alliances and acquisitions will not exceed EUR 50m. In Spain, the objective is to strengthen its presence in the nonprescription products market and in the pet feed sector, an area Faes Farma entered in 2007 through the acquisition of Ingaso Farm. Abroad, its goal is to continue expanding market share, through a joint venture in a country that has not been announced, and through the acquisition of a company in South America. In addition, Faes Farma is considering diversification through subsidiaries or establishing business partnerships in China, Nigeria and Poland, but also its sights are set on Brazil, the Philippines and Malaysia.
(content in spanish)
El grupo farmacéutico español Faes Farma está estudiando nuevas compras tanto en España como en el exterior para seguir reforzando su negocio. Tiene previsto cerrar el 2015 con unos beneficios de EUR 29m, un 16% más que en 2014, alcanzando ventas de hasta EUR 205m. La partida total destinada a alianzas y adquisiciones no superará los EUR 50m. En España, su objetivo es reforzarse en el mercado de los productos sin receta médica y en el sector de alimentación animal, área en el que entró en 2007 con la compra de Ingaso Farm. En el exterior, su objetivo es seguir ampliando mercado, con la creación de una empresa mixta en un país que por el momento no ha concretado, así como la compra de una compañía de Sudamérica. Además, la compañía se está planteando diversificarse implantando filiales o estableciendo alianzas comerciales en China, Nigeria y Polonia, aunque también tiene el ojo puesto en Brasil, Filipinas y Malasia. |
Intel ID | 224160 | |
Value | EUR 50,00m (Approx.) | |
Native Currency | Euro (EUR) | |
Financial Data - Faes Farma
(31 Dec 2023) |
Revenue: EUR 476,92m EBITDA: EUR 122,24m |
|
Date |
![]() |
|
Country | ![]() |
|
Region | ||
Continent | ![]() |
|
Geography | ![]() |
|
Subsector (Old TTR Sectors) |
|
|
Type |
![]() |
|
Intel Grade |
![]() |
|
Source |
![]() |
|
Tags | ![]() |
Bidder
Name |
|
||
Subsector (Old TTR Sectors) |
|
||
Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
Secondary Sectors (TTRSC) |
30.01.01 Biopharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals 30.01.04 Specialty Pharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
Country |
![]() |
||
Website |
![]() |
||
Description |
![]() |
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.